Revised forecast
Fiscal year ending August 2027 · Six months and full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Revenue increased, driven by higher sales in the strong-performing pharmaceutical and healthcare businesses and other factors. Meanwhile, surging raw material and supply prices, increased personnel expenses and higher advertising and promotional expenses resulting from intensified advertising and promotional activities weighed on profit, and ¥435 million in impairment losses on goodwill and fixed assets was recorded as an extraordinary loss.
Impairment losses on goodwill and fixed assets: ¥435 million (¥435,850 thousand in the consolidated income statement)
| Item | Details |
|---|---|
| Net Sales | Not disclosed → 2Q cumulative 17,610 / Full year 35,473（2Q cumulative 4.5 / Full year 3.3） |
| Operating profit | Not disclosed → 2Q cumulative 1,272 / Full year 2,623（2Q cumulative 1.7 / Full year 6.9） |
| Ordinary income | Not disclosed → 2Q cumulative 1,215 / Full year 2,510（2Q cumulative 1.7 / Full year 5.1） |
| Profit attributable to owners of the parent | Not disclosed → 2Q cumulative 815 / Full year 1,658（2Q cumulative 1.8 / Full year 38.3） |
| Net income per share | Not disclosed → 2Q cumulative 56.03 / Full year 113.88 |
| Fiscal Period Covered | Fiscal year ending August 2027 |
| Period Covered | Six months and full year |
| Previous-period results | Revenue: ¥34,324 million; operating profit: ¥2,455 million; ordinary profit: ¥2,390 million; net income attributable to owners of the parent: ¥1,198 million; earnings per share: ¥82.89 (fiscal year ended August 2026) |
| Reason for the revision | Revenue increased, driven by higher sales in the strong-performing pharmaceutical and healthcare businesses and other factors. Meanwhile, surging raw material and supply prices, increased personnel expenses and higher advertising and promotional expenses resulting from intensified advertising and promotional activities weighed on profit, and ¥435 million in impairment losses on goodwill and fixed assets was recorded as an extraordinary loss. |
| Details and amount of extraordinary loss | Impairment losses on goodwill and fixed assets: ¥435 million (¥435,850 thousand in the consolidated income statement) |
| Dividend forecast revision | Annual dividend forecast for the fiscal year ending August 2027: ¥44.00 (interim dividend: ¥22.00; year-end dividend: ¥22.00) |
| Consolidated / non-consolidated | Consolidated / non-consolidated (standalone) |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased, driven by higher sales in the strong-performing pharmaceutical and healthcare businesses. On the earnings front, in addition to higher costs resulting from surging raw material and supply prices, increased personnel expenses and intensified advertising and promotional activities, the company recorded ¥435 million in impairment losses on goodwill and fixed assets.